• Contact
  • Home
  • About
  • Science
    • Publications
  • Pipeline
  • UBX1325
  • Clinical Trials
  • Investors & Media
    • Corporate Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Investor Resources
  • Contact
  • Menu Menu

Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

April 22, 2025/in Featured, Publications/by eallison

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400009

Tags: Ophthalmology
https://unitybiotechnology.com//wp-content/uploads/logo.svg 0 0 eallison https://unitybiotechnology.com//wp-content/uploads/logo.svg eallison2025-04-22 17:56:592025-04-22 17:59:05Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
You might also like
Cellular Senescence Is Associated With Human Retinal Microaneurysm Formation During Aging
UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy
Cellular Senescence Is Associated With Human Retinal Microaneurysm Formation During Aging
Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition

©2025 Unity Biotechnology. All Rights Reserved. Terms & Conditions | Privacy Policy

Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical...
Scroll to top